Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Cullinan Therapeutics (CGEM) Change in Taxes (2022 - 2023)

Cullinan Therapeutics has reported Change in Taxes over the past 2 years, most recently at -$4.2 million for Q2 2023.

Quarterly results put Change in Taxes at -$4.2 million for Q2 2023, down 109.05% from a year ago — trailing twelve months through Dec 2023 was -$4.3 million (down 200.0% YoY), and the annual figure for FY2023 was -$4.3 million, down 200.0%.
Change in Taxes for Q2 2023 was -$4.2 million at Cullinan Therapeutics, down from -$75000.0 in the prior quarter.
Over the last five years, Change in Taxes for CGEM hit a ceiling of $46.5 million in Q2 2022 and a floor of -$35.1 million in Q3 2022.